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 College oAbstract Background and purpose: A main problem in patients with ischemic CVS is the absence
of a blood marker that can be collected to diagnose and predict prognosis. The objective of our
study was to assess if Phosphorylated Neuroﬁlament H (pNF-H) might provide useful diagnostic
and prognostic information in such patients.
Methods: Thirty patients presenting to the critical care department with ischemic CVS were
studied. Blood samples for Phosphorylated Neuroﬁlament H were assayed on admission and after
7 days. Neuroﬁlament levels were correlated with Glasgow coma scale, CT ﬁndings and NIHSS on
admission and after 7 days.
Results: Neuroﬁlament H levels showed a negative correlation with GCS on admission and after
7 days in, ischemic stroke (0.37, 0.56); hence higher neuromarker levels were associated with lower
GCS. There was a negative correlation between neuroﬁlament levels and ASPECTS CT scores
(r= 0.64, 0.89). NIHSS showed positive correlations with neuroﬁlament levels.
Conclusion: Phosphorylated Neuroﬁlament H can be used as a useful tool to assess patients with
acute ischemic CVS. Levels of the neuroﬁlament correlated with the degree of conscious level in
such patients and with CT ﬁndings hence can be used to assess short term prognosis.
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Following CNS injury, certain proteins are released from neu-
rons. A test that can quantify the levels of these released proteins
might provide useful information about the level of injury, and
would be particularly useful if such protein could be detected in
blood. There has been a growing appreciation that many kinds03.004
n and hosting by Elsevier B.V.
106 W.M. Radwan et al.of CNS injury and disease states are the result of axonal injury
and degeneration [1,2]. Accordingly, a convenient method of
detecting ongoing axonal loss might be particularly useful
experimentally and clinically. The perfect marker to detect axo-
nal injury should have several properties; it should be speciﬁc to
axons, it should be profuse enough so that it can be readily
detectable after the signiﬁcant dilution that occurs following
the release into blood, and it should be resistant to proteases
so that it is not broken down prior to or following release.
Numerous studies have tried to identify and characterize candi-
date biochemical surrogate markers for brain damage including
S-100 protein, Glial Fibrillary Acidic Protein (GFAP) andNeu-
ron Speciﬁc Enolase (NSE). These studies establish that these
proteins are expressed predominantly in neurons, astroglia, oli-
godendroglia and other brain cells. They are released into the
brain parenchyma and transit to cerebrospinal ﬂuid (CSF)
and blood in association with acute brain damage and barrier
disruption. Unfortunately, owing to limitations in sensitivity,
speciﬁcity, and standardized quantiﬁcation across multiple lab-
oratories and studies, none of these proteins has emerged as a
widely used diagnostic or prognostic clinical tool or a validated
surrogate measure for brain damage. Studies that correlate such
protein levels with various clinical outcomes are lacking.
Over the last 20 years, many steps have been taken in the classi-
ﬁcation of Neuroﬁlament proteins and their functions. Early stud-
ies by Hsieh et al have shown that phosphorylation of
neuroﬁlaments is required for the proper functioning of axons by
regulating axons’ diameter.[10] The Neuroﬁlament H protein
sequence contains unusual tandemly repeated 6–8-amino-acid se-
quences centered on the sequence lysine–serine–proline. The serine
residuesof theKSPare phosphorylated [3] andare axon speciﬁc [4].
This phosphorylated form of NF-H (here referred to as pNF-H) is
known to be more resistant to calpain and other proteases [5,6]
Also, pNF-H is highly immunogenic, and the multiple repeated
phosphorylated sites are an excellent target for antibody-based
assays. Taken together, these facts suggest that pNF-H might be
a good candidate for a biomarker of axonal injury.
Patients and methods
Study design
This randomized study was prospectively conducted on 30 pa-
tients presenting to the Critical Care Department Cairo University
Hospitals during the period from January 2010 to January 2011.
Informed written consents had been obtained from the relatives
and the study was approved by the Hospital’s Ethics Committee.
Inclusion criteria
Thirty patients presenting to the Critical Care Department of
the University of Cairo Hospitals with ischemic Cerebrovascu-
lar stroke were enrolled in the study. Ischemic Cerebrovascular
Stroke was deﬁned as the presence of a neurological deﬁcit with
a clearly deﬁned time of onset, and a baseline CT scan of the
brain that shows no evidence of intracranial hemorrhage.
Exclusion criteria
The following patients were excluded:-
 Patients with chronic neurological disease.
 Patients with seizure activity. Patients with renal impairment.
 Patients with Multi-organ Failure Syndrome.
 Patients with multiple trauma.
 Patients younger than 18 years and older than 65 years.
 Patients who were receiving or candidates for thrombolytic
therapy.
Five patients were excluded, because they had one or more
reason for exclusion.
Methods
 Full history taking from the patients, relatives or witnesses
with stress on the onset of neurological symptoms.
 Complete general and focused neurological examination.
 Blood samples were taken for routine labs and for pNF-H
levels. Samples were taken within the ﬁrst 24 h (pNF-H1)
and after 7 days (pNF-H2).
 Non-contrast CT brain (NCCT) on admission and after
7 days. Image review was independently performed on a
workstation by radiologists or neurologists. ASPECTS
CT score was used to assess CT ﬁndings.
 Glasgow coma scale was calculated on admission (GCS1)
and repeated after 7 days (GCS2).
 TheNational Institute ofHealth Stroke Scale (NIHSS)was used
on admission (NIHSS1) and after 7 days (NIHSS2). The level of
stroke severity was measured by the NIH stroke scale scoring
system:0 = i, 1–4 =minor stroke, 5–15 = moderate stroke,
15–20 = moderate/severe stroke, 21–42 = severe stroke.
The ASPECTS score
The Alberta stroke program early CT score (ASPECTS) is a
10-point quantitative topographic CT scan score used in pa-
tients with ischemic stroke. Segmental assessment is made
and 1 point is removed from the initial score of 10 if there is
evidence of infarction in the following regions [7]:
 Caudate.
 Putamen.
 Internal capsule.
 Insular cortex.
 M1: ‘‘anterior MCA cortex,’’ corresponding to frontal
operculum.
 M2: ‘‘MCA cortex lateral to insular ribbon’’ corresponding
to anterior temporal lobe.
 M3: ‘‘posterior MCA cortex’’ corresponding to posterior
temporal lobe.
 M4: ‘‘anterior MCA territory immediately superior to M1’’.
 M5: ‘‘lateral MCA territory immediately superior to M2’’.
 M6: ‘‘posterior MCA territory immediately superior to
M3’’.
The ASPECTS score was calculated on each of the CTs done
to every patient in Group B on admission and after 7 days.
Neuroﬁlament H assay method
Blood samples were drawn from each patient on admission
and after 7 days. The BioVendor Human Phosphorylated
Figure 2 Correlation between Neuroﬁlament H and ASPECTS
score.
Figure 3 Correlation of Neuroﬁlament H with NIHSS.
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ples were placed and left in microplate wells that contained
chicken polyclonal anti-pNF-Hantibody.One hour later, detec-
tion rabbit polyclonal anti-pNF-H antibody was added and
incubated with captured pNF-H for 60 min. After another
wash, horseradish peroxidase (HRP) conjugated antibody
against rabbit antibody was added. After 60 min of incubation
and the last washing step, the remaining conjugate was allowed
to react with the substrate solution. The reactionwas stopped by
the addition of acidic solution and absorbance of the resulting
yellow product was measured.
Data analysis
The Pearson correlation analysis of data was performed using
Statistical Package for the Social Sciences (SPSS) software.
The association of subject characteristics to pNF-H levels was
studied with multiple regressions. Neuroﬁlament H data were
square root transformed to effect normality of distribution of
residuals. Relationships between the square root of pNF-Hwere
investigated within groups with the Pearson correlation and the
two-sample t-test. Analysis of correlation was used to assess the
different relationships between pNF-H and other variables.
Results
General characteristics of patients
The study of demographic characteristics of the patients
showed a mean age of 49 years with a range of 49–51 years.
Males represented 60% of the population. Out of the thirty pa-
tients studied, 22 patients were diabetics (73%), 21 were dyslip-
idemics (70%), 16 were smokers (53%) and 22 were
hypertensive (73%). The mean GCS on admission (GCS1)
was 7.1 and was 8.1 after 7 days (GCS2).
Mean Neuroﬁlament H levels
The mean Neuroﬁlament level (pNF-H1) was 35.4 ± 21 pg/ml
on admission and was 89.3 ± 54.7 after 7 days (pNF-H2).
Hence the Neuroﬁlament level was signiﬁcantly higher after
7 days (p< 0.005).
Correlation between GCS and p-NFH levels
As shown by the scatter diagram there was a negative correla-
tion between the level of Neuroﬁlament H and the GlasgowFigure 1 Correlation of Phosphorylated Neuroﬁlament H with
Glasgow Coma.Coma Scale on admission and after 7 days in patients with
ischemic CVS (0.374, 0.51 with P< 0.005) (Fig. 1).
Mean ASPECTS score
CT assessment showed the mean ASPECTS score was 8.1 on
admission and 6.7 after 7 days. The difference was statistically
signiﬁcant, lower after 7 days hence most patients with ische-
mic CVS showed an increase in infarct size after 7 days
p< 0.005).
Correlation between ASPECTS score and mean Neuroﬁlament
levels
There was a negative correlation between the level of Neuroﬁl-
ament detected and the ASPECTS scores on admission and
after 7 days (0.64 and 0.89, respectively, p< 0.005). In
other words, the higher the level of pNF-H the lower the AS-
PECTS score (Fig. 2).
Correlation between Neuroﬁlament H levels and NIHSS
There was a positive correlation between the Neuroﬁlament le-
vel and the NIHSS patients (0.55 on admission and 0.8 after
7 days p< 0.005) (Fig. 3).
Discussion
Our results show that pNF-H is quantiﬁable in the blood of
patients with ischemic CVS and hence the appearance of this
form of neuroﬁlaments in the serum of humans might indicate
108 W.M. Radwan et al.a neuronal injury. Blood collection is more practical and safer
than CSF sampling, this suggests that analysis of blood for
pNF-H could be a useful clinical tool to conveniently assess,
diagnose and follow up patients with ischemic CVS. Other
studies have shown that vertebrate neurons are sensitive to
mechanical and metabolic damage and a major portion of
the pathophysiology following ischemic CVS is due to axonal
damage [1]. Therefore, a convenient blood assay of axonal loss
could be of great utility.
Our results showed that there was a signiﬁcant increase in
the mean pNF-H levels in patients with ischemic CVS after
7 days (from 35 to 89 pg/ml). This indicated that the process
of neuronal degeneration in ischemic CVS is an ongoing pro-
cess that does not stop with the primary ischemic insult but
continues on for days and weeks.
We showed a signiﬁcant correlation between the GCS and
hence the degree of consciousness and the mean pNF-H value
i.e. those with higher pNF-H levels had lower GCS. This is of
great importance as the GCS is a frequently utilized score that
assess changes in consciousness, and the presence of a signiﬁ-
cant correlation with the GCS is a point that gives strength
to our marker studied.
ASPECTS CT score showed a negative correlation with
pNF-H, which again means that higher levels of the marker
were found in those with a lower ASPECTS score and hence
worse CT ﬁndings. The mean ASPECTS score was lower after
7 days indicating an increase in infarct size, and this also cor-
related with a higher pNF-H levels. This denotes that our mar-
ker might be able to predict an increase in the infarct size in
patients with ischemic CVS.
Our data showed a positive correlation between pNF-H
and NIHSS scale i.e. those with higher NIHSS and hence
greater disability had higher mean pNF-H levels both on
admission and after 7 days. Again this shows that our marker
is able to detect levels of disability in patients with ischemic
CVS.
Sellner et al. [8] studied serum biomarkers in patients pre-
senting with acute stroke. They studied 18 patients (15 ische-
mic, 3 hemorrhagic) and analyzed 3 biomarkers:
neuroﬁlaments, S-100 proteins and Glial Fibrillary Acidic Pro-
tein (GFAP). Serial blood samples were collected, starting
within the ﬁrst 6 h and daily up to 6 days. Their data showed
a signiﬁcant increase in neuroﬁlament levels within the ﬁrst day
and at all other times compared to the S-100B, and GFAP was
not detected at any time in all patients. Although their study
showed an increase in the level of neuroﬁlament in ischemic
stroke patients, they did not correlate their ﬁndings with the
clinical parameters  as GCS or NIHSS – or with radiological
ﬁndings.
Sing et al. [9] measured levels of pNF-H in stroke and cor-
related these levels with measures of stroke severity. Blood
samples were collected from 54 ischemic stroke patients at
day 1, week 1 (days 7–10) and weeks 3–6, and an ELISA
was used to measure pNF-H levels in each patient at each
time-point. Serum pNF-H levels were signiﬁcantly elevated
in stroke patients compared to healthy controls. Blood pNF-
H levels that reﬂect the severity of ischemic stroke correlated
with outcome and rise during the weeks after stroke. Similarlyin our study, the pNF-H levels correlated with the severity of
the stroke as reﬂected by GCS, ASCPECTS and NIHSS.
An important issue to mention is, if Neuroﬁlaments are lo-
cated in axons, axonal loss is a major problem in many kinds
of human neurological damage and disease states, such as
Traumatic brain injury, multiple sclerosis, and amyotrophic
lateral sclerosis. This can be problematic in patients with
chronic CNS disease and those with multiple co-morbidities.
Although we excluded those patients with any chronic CNS
diseases, in real clinical practice this will be hard.
Conclusion
Neuroﬁlament H is detected in the plasma of patients with
acute ischemic CVS. Levels of Neuroﬁlament H correspond
to the severity of injury as shown by the presence of signiﬁcant
correlations between Neuroﬁlament levels and GCS, NIHSS
and the radiological ﬁndings. Thus Neuroﬁlament H seems
to be a promising marker for the diagnosis and prognosis of
patients with ischemic CVS and for the short term follow up
of such patients. However, further studies will be needed to
complement our results in larger groups of patients. A more
speciﬁc study of the pattern of rise, fall and peak of the marker
will be very helpful in this group of patients.
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